Is the detection of early markers of Epstein Barr virus of diagnostic value?

Posted By News On November 16, 2012 - 8:30pm
Is the detection of early markers of Epstein Barr virus of diagnostic value?

New Rochelle, NY, November 15, 2012—Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and a risk for serious disease in liver transplant recipients. Molecular tests that can identify early protein markers produced by EBV may have value for diagnosing active infection. The benefits of this diagnostic approach in patients with mononucleosis and in EBV-infected transplant patients are evaluated in an article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Andrea Crowley, Jeff Connell, Kirsten Schaffer, William Halla, and Jaythoon Hassan, University College Dublin and St. Vincent's University Hospital, Dublin, Ireland, compared three immunoassay methods for detecting antibodies produced by the body in response to EBV infection and the presence of proteins that comprise the EBV early antigen complex. The researchers determined which of the diagnostic tests could better predict EBV infection in patients with mononucleosis or in immunosuppressed adult liver transplant recipients. The article "Is There Diagnostic Value in Detection of Immunoglobulin G Antibodies to the Epstein–Barr Virus Early Antigen?" presents the complete methodology and results of this study.

BioResearch Open Access is published online six times per year. For more information visit

(Photo Credit: ©2012, Mary Ann Liebert, Inc., publishers)

"Having the ability to predict the risk of developing EBV-induced lymphoproliferative disorders after a transplant has important consequences for patient care, as it would allow for prompt therapy and could potentially decrease patient mortality," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

I was just scouring through the net while i was doing research on EBV.

I believe HSP90 Inhibitors has been developed for treating many complications related to EBV. Is this drug useful in treating EBV infections and the chronic fatigue associated with it too?. How safe are these drugs and have they been FDA approved?

I have seen that these inhibitors have been found to be toxic in previous clinical trials. Have any developments been made in the treatment of EBV and related symptoms/complications etc.?

Do you still recommend valcyte or valgancyclovir or famvir for people who have been infected with EBV, i was diagnosed with this infection way back in february. Life has been very difficult, i find it hard to focus and maintain a normal life.

If there are any new treatments in the market that has proven to work against EBV, id like to know about it.

Please let me know what i need to do.


Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <h> <a> <em> <img> <strong> <object> <cite><p><br><i><b><center><ul><li><div><html5:figure><html5:figcaption>
  • Lines and paragraphs break automatically.

More information about formatting options

Sorry, we know you're not a spambot, but they're out there